What Researchers Did
Researchers conducted a randomized controlled trial with 20 lung transplant recipients to compare hyperbaric oxygen therapy (HBOT) against usual care for preventing central airway stenosis.
What They Found
The trial was stopped early after an interim analysis showed no difference between HBOT and usual care groups in stenting (both 40%), acute cellular rejection (70% vs 40%), or central airway stenosis (40% vs 60%). However, time to first stent placement was significantly shorter in the HBOT group (150 days vs 186 days, p < 0.05). Gene expression analysis revealed higher HMOX1 and VEGFA in subjects with CAS or stenting, and FLT1, TIE2, and KDR in those with acute cellular rejection.
What This Means for Canadian Patients
For Canadian lung transplant patients, hyperbaric oxygen therapy (HBOT) does not appear to prevent central airway stenosis or acute cellular rejection. In fact, it might even lead to earlier stent placement, suggesting it is not a beneficial treatment for this complication.
Canadian Relevance
This study has no direct Canadian connection as it was not conducted in Canada or with Canadian participants.
Study Limitations
A significant limitation of this study is its premature termination after enrolling only 20 subjects, limiting the power to detect differences.